The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
On a facility basis, based on the size of the manufacturing facility.
82%
On a company basis, based on company revenues.
6%
On a company basis, based on the number of manufacturing facilities operated by the company.
12%
A flat fee for all companies with pharmaceutical manufacturing facilities.
Jim Miller
Founder and President
PharmSource
Information Services
Insights into trends and challenges facing contract service providers and users in the pharmaceutical and biopharmaceutical industries.
May 2008 CMOs are Planning for the Last War
CMO business models are out of touch with current pharma industry realities. It's time for new thinking. continue reading
April 2008 Weak Link in the Pharmaceutical Supply Chain
The recent heparin contamination event calls for a new approach to manage a lengthening pharmaceutical supply chain. continue reading
sponsored by
Patrica Van Arnum
Senior Editor
Pharmaceutical Technology
Magazine
Get the latest business and scientific developments in manufacturing active pharmaceutical ingredients, intermediates, and excipients.
May 2008 Unfolding Catalytic Routes to APIs
Chemocatalytic and biocatalytic routes show promise for more efficient syntheses of select active ingredients.
continue reading
April 2008 Measuring Excipient-Market Growth
Moderate growth is projected for the global excipients market. Excipient producers target blends and new grades for improving functionality and performance.
continue reading
